
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (0)
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Remove Labelling/Packaging filter Labelling/Packaging (1)
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Remove Manufacturing filter Manufacturing (1)
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Medicinal cannabis (1) Apply Medicinal cannabis filter
- Remove Medicines filter Medicines (2)
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Remove Other therapeutic goods filter Other therapeutic goods (1)
- Prescription medicines (6) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Manufacturing filter Manufacturing
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Blood and blood components filter Blood and blood components
- (-) Remove Other therapeutic goods filter Other therapeutic goods
- (-) Remove Labelling/Packaging filter Labelling/Packaging
- (-) Remove Medicines filter Medicines
Repurposing of medicines
Closed on 1 April 2022
Consultation on Extemporaneous Compounding of Emergency Medicines
Closed on 7 February 2022
Proposal for clarifying regulatory requirements for residual claims for disinfectants
Closed on 26 March 2021
Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirement
Closed on 29 January 2021
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020
Labelling project 99/00 Effective by design
Closed on 23 June 2000